...
首页> 外文期刊>Bone >The association between insulin use and volumetric bone mineral density, bone micro-architecture and bone strength of the distal radius in patients with type 2 diabetes – The Maastricht study
【24h】

The association between insulin use and volumetric bone mineral density, bone micro-architecture and bone strength of the distal radius in patients with type 2 diabetes – The Maastricht study

机译:2型糖尿病患者胰岛素使用和体积骨密度,骨微架和骨强度的关系 - Maastricht研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Type 2 diabetes mellitus (T2DM) has been associated with an increased risk of fractures, despite normal to increased bone mineral density (BMD). Insulin use is one of the factors linked to this increased fracture risk. However, direct negative effects of insulin on bone quality are not expected since insulin is thought to be anabolic to bone. In this cross-sectional study the association between insulin use and volumetric BMD (vBMD), bone micro-architecture and bone strength of the distal radius, as measured with HR-pQCT, was examined. Data from 50 participants with T2DM of The Maastricht Study (mean age 62 ± 7.5 years, 44% women) was used. Participants were classified as insulin user (n = 13) or non-insulin user (n = 37) based on prescription data. Linear regression analysis was used to estimate the association between current insulin use and HR-pQCT derived parameters. After adjustment for age, sex, body mass index, glycated hemoglobin A1c and T2DM duration, insulin use was associated with lower total vBMD (standardized beta (β):? 0.56 (95% CI:? 0.89 to ? 0.24)), trabecular vBMD (β:? 0.58 (95% CI:? 0.87 to ? 0.30)), trabecular thickness (β:? 0.55 (95% CI:? 0.87 to ? 0.23)), cortical thickness (β:? 0.41 (95% CI:? 0.74 to ? 0.08)), log cortical pore volume (β:? 0.43 (95% CI:? 0.73 to ? 0.13)), bone stiffness (β:? 0.39 (95% CI:? 0.62 to ? 0.17)) and failure load (β:? 0.39 (95% CI:? 0.60 to ? 0.17)) when compared to the non-insulin users. Insulin use was not associated with cortical vBMD, trabecular number, trabecular separation, cortical porosity and cortical pore diameter. This study indicates that insulin use is negatively associated with bone density, bone micro-architectural and bone strength parameters. These findings may partly explain the previously observed increased fracture risk in insulin users, although there may be residual confounding by other factors related to disease severity in insulin users. ]]>
机译:摘要表2型糖尿病(T2DM)与骨折的骨折风险增加有关,尽管骨矿物密度(BMD)正常。胰岛素使用是与这种增加的骨折风险相关的因素之一。然而,由于胰岛素被认为是对骨骼的代谢物,因此不会预期胰岛素对骨质质量的直接负面影响。在这种横截面研究中,检查了用HR-PQCT测量的胰岛素使用和体积BMD(VBMD),远端半径的骨微结构和远端半径的骨强度。 50名与马斯特里赫特T2DM的参与者的数据(平均62±7.5岁,44%的女性)。基于处方数据,参与者被分类为胰岛素用户(n = 13)或非胰岛素用户(n = 37)。线性回归分析用于估计当前胰岛素使用和HR-PQCT衍生参数之间的关联。在调整年龄,性别,体重指数,糖化血红蛋白A1C和T2DM持续时间后,胰岛素使用与较低的总VBMD(标准化β(β):0.56(95%CI:0.89至0.24))相关,小梁VBMD (β:? 0.58(95%CI:0.87至0.30)),小梁厚度(β:? 0.55(95%CI:0.87至0.23)),皮质厚度(β:? 0.41(95%CI: ?0.74至0.08)),Log皮质孔体积(β:? 0.43(95%Ci:0.73至约0.13)),骨刚度(β:? 0.39(95%Ci:0.62至约0.17))和与非胰岛素用户相比,失效载荷(β:? 0.39(95%CI:0.60至约10.17))。胰岛素使用与皮质VBMD,小梁数,小梁分离,皮质孔隙率和皮质孔径无关。本研究表明,胰岛素使用与骨密度,骨微架构和骨强度参数负相关。这些发现可以部分解释前面观察到的胰岛素用户的增加的骨折风险,尽管可能与胰岛素用户疾病严重程度有关的其他因素可能存在残留的混淆。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号